Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study

Abstract Background The rate of primary and secondary treatment while on active surveillance (AS) for localized prostate cancer at the general population level is unknown. Our objective was to determine the patterns of secondary treatments after primary surgery or radiation for patients who undergo...

Full description

Bibliographic Details
Main Authors: Rano Matta, Amanda E. Hird, Erind Dvorani, Refik Saskin, Gregory J. Nason, Girish Kulkarni, Ronald T. Kodama, Sender Herschorn, Robert K. Nam
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.3341
_version_ 1826937836994035712
author Rano Matta
Amanda E. Hird
Erind Dvorani
Refik Saskin
Gregory J. Nason
Girish Kulkarni
Ronald T. Kodama
Sender Herschorn
Robert K. Nam
author_facet Rano Matta
Amanda E. Hird
Erind Dvorani
Refik Saskin
Gregory J. Nason
Girish Kulkarni
Ronald T. Kodama
Sender Herschorn
Robert K. Nam
author_sort Rano Matta
collection DOAJ
description Abstract Background The rate of primary and secondary treatment while on active surveillance (AS) for localized prostate cancer at the general population level is unknown. Our objective was to determine the patterns of secondary treatments after primary surgery or radiation for patients who undergo AS. Methods This was a population‐based retrospective cohort study of men aged 50‐80 years old in Ontario, Canada, between 2008 and 2016. We identified 26 742 patients with prostate cancer, a Gleason grade score ≤7, and an index prostate‐specific antigen ≤10 ng/mL. Patients were categorized as undergoing AS with or without delayed primary treatment (DT; treatment >6 months after diagnosis) versus immediate treatment (IT; treatment ≤6 months). Patients receiving DT and IT were propensity score matched and the rate of secondary treatment (surgery or radiation ± androgen deprivation treatment) was compared using Cox proportional hazards models. Results We identified 10 214 patients who underwent AS and 11 884 patients who underwent IT. Among patients undergoing AS, 3724 (36.5%) eventually underwent DT and among them, 406 (10.9%) underwent secondary treatment. The median time to DT was 1.2 years (IQR 0.5‐8.1 years). The relative rate of undergoing secondary treatment was similar in the DT vs IT group (HR 0.92; 95% CI: 0.79‐1.08). The risk of death in the DT group was higher compared to patients who did not undergo treatment (HR 1.23, 95% CI: 1.01‐1.49). Conclusions Among patients with localized prostate cancer on AS, one third undergo DT. The rate of secondary treatment was similar between the DT and IT groups. Patients in the DT group may experience a higher risk of mortality compared to those who remained on AS.
first_indexed 2024-04-09T15:57:16Z
format Article
id doaj.art-62e897e9eeb74d919c0a9dfa94d4a2f7
institution Directory Open Access Journal
issn 2045-7634
language English
last_indexed 2025-02-17T18:47:58Z
publishDate 2020-10-01
publisher Wiley
record_format Article
series Cancer Medicine
spelling doaj.art-62e897e9eeb74d919c0a9dfa94d4a2f72024-12-11T08:05:11ZengWileyCancer Medicine2045-76342020-10-019196946695310.1002/cam4.3341Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort studyRano Matta0Amanda E. Hird1Erind Dvorani2Refik Saskin3Gregory J. Nason4Girish Kulkarni5Ronald T. Kodama6Sender Herschorn7Robert K. Nam8Division of Urology Sunnybrook Health Sciences Centre University of Toronto Toronto ON CanadaDivision of Urology Sunnybrook Health Sciences Centre University of Toronto Toronto ON CanadaInstitute of Clinical Evaluative Sciences University of Toronto Toronto ON CanadaInstitute of Clinical Evaluative Sciences University of Toronto Toronto ON CanadaDivision of Urology Sunnybrook Health Sciences Centre University of Toronto Toronto ON CanadaInstitute of Health Policy, Management and Evaluation University of Toronto Toronto ON CanadaDivision of Urology Sunnybrook Health Sciences Centre University of Toronto Toronto ON CanadaDivision of Urology Sunnybrook Health Sciences Centre University of Toronto Toronto ON CanadaDivision of Urology Sunnybrook Health Sciences Centre University of Toronto Toronto ON CanadaAbstract Background The rate of primary and secondary treatment while on active surveillance (AS) for localized prostate cancer at the general population level is unknown. Our objective was to determine the patterns of secondary treatments after primary surgery or radiation for patients who undergo AS. Methods This was a population‐based retrospective cohort study of men aged 50‐80 years old in Ontario, Canada, between 2008 and 2016. We identified 26 742 patients with prostate cancer, a Gleason grade score ≤7, and an index prostate‐specific antigen ≤10 ng/mL. Patients were categorized as undergoing AS with or without delayed primary treatment (DT; treatment >6 months after diagnosis) versus immediate treatment (IT; treatment ≤6 months). Patients receiving DT and IT were propensity score matched and the rate of secondary treatment (surgery or radiation ± androgen deprivation treatment) was compared using Cox proportional hazards models. Results We identified 10 214 patients who underwent AS and 11 884 patients who underwent IT. Among patients undergoing AS, 3724 (36.5%) eventually underwent DT and among them, 406 (10.9%) underwent secondary treatment. The median time to DT was 1.2 years (IQR 0.5‐8.1 years). The relative rate of undergoing secondary treatment was similar in the DT vs IT group (HR 0.92; 95% CI: 0.79‐1.08). The risk of death in the DT group was higher compared to patients who did not undergo treatment (HR 1.23, 95% CI: 1.01‐1.49). Conclusions Among patients with localized prostate cancer on AS, one third undergo DT. The rate of secondary treatment was similar between the DT and IT groups. Patients in the DT group may experience a higher risk of mortality compared to those who remained on AS.https://doi.org/10.1002/cam4.3341active surveillancemortalityprostate cancerprostatic neoplasmsrecurrence
spellingShingle Rano Matta
Amanda E. Hird
Erind Dvorani
Refik Saskin
Gregory J. Nason
Girish Kulkarni
Ronald T. Kodama
Sender Herschorn
Robert K. Nam
Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study
Cancer Medicine
active surveillance
mortality
prostate cancer
prostatic neoplasms
recurrence
title Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study
title_full Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study
title_fullStr Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study
title_full_unstemmed Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study
title_short Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study
title_sort rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer a population based cohort study
topic active surveillance
mortality
prostate cancer
prostatic neoplasms
recurrence
url https://doi.org/10.1002/cam4.3341
work_keys_str_mv AT ranomatta ratesofprimaryandsecondarytreatmentsforpatientsonactivesurveillanceforlocalizedprostatecancerapopulationbasedcohortstudy
AT amandaehird ratesofprimaryandsecondarytreatmentsforpatientsonactivesurveillanceforlocalizedprostatecancerapopulationbasedcohortstudy
AT erinddvorani ratesofprimaryandsecondarytreatmentsforpatientsonactivesurveillanceforlocalizedprostatecancerapopulationbasedcohortstudy
AT refiksaskin ratesofprimaryandsecondarytreatmentsforpatientsonactivesurveillanceforlocalizedprostatecancerapopulationbasedcohortstudy
AT gregoryjnason ratesofprimaryandsecondarytreatmentsforpatientsonactivesurveillanceforlocalizedprostatecancerapopulationbasedcohortstudy
AT girishkulkarni ratesofprimaryandsecondarytreatmentsforpatientsonactivesurveillanceforlocalizedprostatecancerapopulationbasedcohortstudy
AT ronaldtkodama ratesofprimaryandsecondarytreatmentsforpatientsonactivesurveillanceforlocalizedprostatecancerapopulationbasedcohortstudy
AT senderherschorn ratesofprimaryandsecondarytreatmentsforpatientsonactivesurveillanceforlocalizedprostatecancerapopulationbasedcohortstudy
AT robertknam ratesofprimaryandsecondarytreatmentsforpatientsonactivesurveillanceforlocalizedprostatecancerapopulationbasedcohortstudy